AccuPSA is a straightforward blood test that may tell a physician important information about prostate specific antigen amounts after radical prostatectomy, stated David Wilson, Ph.D., senior director of item development at Quanterix Company, the manufacturer of the test. AccuPSA gets the potential to get rid of unnecessary treatments and enable earlier recognition of recurrence, which may lead to earlier treatment, better outcomes and have a positive impact on healthcare costs. Related StoriesOvarian cancer patients with a history of oral contraceptive use have got better outcomesSausages With Antioxidants From Berries TO AVOID CancerNew RNA test of blood platelets can be used to detect location of cancerAfter going through radical prostatectomy, a lot of men remain at a significant risk for malignancy recurrence.In concert they’ll form a fundamental element of the clinically relevant discoveries the Consortium aims to make.’ Related StoriesCrucial change in single DNA bottom predisposes children to intense type of cancerViralytics enters into clinical trial collaboration agreement with MSDStudy shows uncommon HER2 missense mutations usually do not spread breasts cancer on their ownScientists from the National Malignancy Institute , FDA, and nearly 20 major cancer research centers across the USA have united to develop and carry out this unprecedented large-level scientific collaboration to test novel breast cancer medicines in the neoadjuvant scientific trial setting.